We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+20.66%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$352M
Cap. Flow
-$18.8M
Cap. Flow %
-0.71%
Top 10 Hldgs %
38.92%
Holding
218
New
26
Increased
62
Reduced
55
Closed
4

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.4M
3
ABT icon
Abbott
ABT
+$12.5M
4
MIST icon
Milestone Pharmaceuticals
MIST
+$12.4M
5
CI icon
Cigna
CI
+$12M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$146M
2
UNH icon
UnitedHealth
UNH
+$23.1M
3
ISRG icon
Intuitive Surgical
ISRG
+$9.43M
4
HUM icon
Humana
HUM
+$9.27M
5
ZTS icon
Zoetis
ZTS
+$7.29M

Sector Composition

Rank Sector Weight
1 Healthcare 94.16%
2 Real Estate 3.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMGN icon
1
Amgen
AMGN
$209B
$149M 5.63%
617,427
-14,860
-2% -$3.28M
JNJ icon
2
Johnson & Johnson
JNJ
$617B
$134M 5.06%
916,827
+98,600
+12% +$13.4M
GILD icon
3
Gilead Sciences
GILD
$163B
$123M 4.65%
1,890,576
+56,594
+3% +$3.69M
MRK icon
4
Merck
MRK
$321B
$110M 4.17%
1,269,530
– –
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$122B
$108M 4.09%
493,789
+6,555
+1% +$1.33M
ILMN icon
6
Illumina
ILMN
$31B
$90.4M 3.42%
280,234
+32,343
+13% +$9.8M
BIIB icon
7
Biogen
BIIB
$30.7B
$84.6M 3.2%
285,126
+27,187
+11% +$7.54M
PFE icon
8
Pfizer
PFE
$142B
$81.7M 3.09%
2,197,957
-30,522
-1% -$1.09M
REGN icon
9
Regeneron Pharmaceuticals
REGN
$77.4B
$75.6M 2.86%
201,277
+41,619
+26% +$14M
UNH icon
10
UnitedHealth
UNH
$383B
$73.2M 2.77%
248,829
-88,454
-26% -$23.1M
MDT icon
11
Medtronic
MDT
$110B
$53.4M 2.02%
470,812
+71,442
+18% +$7.84M
BMY icon
12
Bristol-Myers Squibb
BMY
$132B
$49.7M 1.88%
774,862
+36,818
+5% +$2.11M
ALXN
13
DELISTED
Alexion Pharmaceuticals
ALXN
$47.1M 1.78%
435,814
-18,073
-4% -$1.93M
ABT icon
14
Abbott
ABT
$183B
$41M 1.55%
471,835
+149,322
+46% +$12.5M
TMO icon
15
Thermo Fisher Scientific
TMO
$214B
$40.1M 1.52%
123,408
+34,098
+38% +$10.3M
CI icon
16
Cigna
CI
$76.1B
$39M 1.47%
190,555
+65,560
+52% +$12M
CVS icon
17
CVS Health
CVS
$134B
$37M 1.4%
497,986
-42,300
-8% -$2.97M
INCY icon
18
Incyte
INCY
$24.9B
$33.5M 1.27%
383,230
-10,500
-3% -$897K
SGEN
19
DELISTED
Seagen Inc. Common Stock
SGEN
$31.6M 1.2%
276,766
-13,159
-5% -$1.4M
ELV icon
20
Elevance Health
ELV
$81.6B
$30.8M 1.17%
102,032
-19,100
-16% -$5.26M
AGN
21
DELISTED
Allergan plc
AGN
$30.5M 1.15%
159,581
+14,300
+10% +$2.58M
ABBV icon
22
AbbVie
ABBV
$455B
$30.2M 1.14%
340,916
-59,100
-15% -$4.91M
LLY icon
23
Eli Lilly
LLY
$1.03T
$27.6M 1.04%
210,181
+53,223
+34% +$6.17M
BSX icon
24
Boston Scientific
BSX
$68.4B
$25.5M 0.97%
564,345
-605
-0.1% -$25.3K
DHR icon
25
Danaher
DHR
$138B
$25.4M 0.96%
186,657
+14,777
+9% +$1.87M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Tekla Capital Management held 218 positions worth $2.64B, up 15% from $2.29B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2019 filing shows 26 new, 62 increased, 55 reduced and 4 closed positions. Its largest new stake was Centene: 149,526 shares worth $9.4M. The largest sale was Celgene Corp, an estimated $146M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2019 buy was Centene: 149,526 shares worth $9.4M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q4 2019, an estimated $14M increase.
  • Tekla Capital Management's biggest Q4 2019 reduction was UnitedHealth, cutting an estimated $23.1M.
  • Tekla Capital Management fully exited Celgene Corp in Q4 2019, selling an estimated $146M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.64B portfolio in Q4 2019.
  • Tekla Capital Management opened 26 new positions and closed 4 in Q4 2019.
  • Tekla Capital Management's portfolio value rose 15% quarter-over-quarter to $2.64B.

Based on Tekla Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.